For the third quarter of 2002, Trimeris Inc. (Nasdaq: TRMS) reported a loss of $18.1 million, or 97 cents per share, compared with a loss of $15 million, or 86 cents per share in the comparable 2001 period.

Excluding non-cash compensation charges and credits, Trimeris’ net loss for the third quarter of 2002 was $17.6 million, or 94 cents per share, compared to $16.2 million or 93 cents per share for the third quarter of 2001.

Trimeris says the increase in net loss for the quarter is primarily due to increased expenses incurred for pre-launch marketing of Fuzeon, formerly known as T-20, less reduced expenses incurred for the production of drug material for clinical trials. These costs are net of reimbursements from Hoffmann-La Roche, the company’s collaborative partner.

Cash and cash equivalents and short-term investments totaled $61.1 million at Sept. 30, 2002.

Trimeris closed a public offering in October that resulted in proceeds of $106.9 million after deducting applicable offering expenses.

“The past several months have been exciting for Trimeris as we have made substantial progress toward the anticipated commercialization of Fuzeon, our lead fusion inhibitor product candidate for HIV,” Dani Bolognesi, chief executive officer of Trimeris, said in a statement. “Together with our partner Roche, we submitted regulatory applications in the U.S. and European Union and received priority review status from the FDA. We were also pleased with our follow-on offering completed in October and the continued support of our investors to help bring Fuzeon to market.”